LPAA
Launch One Acquisition Corp.10.59
+0.03+0.28%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
304.46MP/E (TTM)
35.30Basic EPS (TTM)
0.30Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
Launch One Acquisition Corp. posted a net income of $1.9M for Q2 FY2025 ended June 30, 2025, swinging from a $22K loss a year earlier, thanks to $2.5M in interest from its Trust Account—now at $240.5M after accretion—while general and administrative costs climbed to $638K from formation expenses. Six-month net income hit $4.2M, with EPS at $0.15 for both redeemable Class A and non-redeemable Class B shares, reconciling neatly to 23M and 5.75M diluted shares outstanding. Cash outside the Trust dipped to $264K amid $587K used in operations, but no debt burdens the balance sheet. The SPAC inked a business combination with Minovia Therapeutics on June 25, 2025, for $180M in Pubco shares plus earnouts, amended August 12 to extend bridge financing timelines. Solid Trust growth offsets rising costs. Yet regulatory hurdles in Israel could snag the deal.
8-K
Launch One SPAC merges with Minovia
Launch One Acquisition Corp. signed a business combination agreement on June 25, 2025, to merge with Minovia Therapeutics Ltd., forming Mito US One Ltd. as the public entity listed on Nasdaq. Minovia shareholders will receive $180 million in Pubco shares at the redemption price, plus potential $57.5 million earnout shares over five years tied to stock price or FDA milestones for Pearson syndrome. The deal requires $23 million minimum cash post-redemptions and financing, yet hinges on approvals amid IP and regulatory risks.
8-K
SPAC merger with Minovia announced
Launch One Acquisition Corp. signed a business combination agreement with Minovia Therapeutics on June 25, 2025, valuing Minovia at $180 million pre-money, plus at least $5 million bridge financing and $18 million PIPE, with $57.5 million earnout potential. The deal merges Minovia's mitochondrial augmentation technology—showing safety in 23 patients and FDA Fast Track for Pearson Syndrome—into a Nasdaq-listed entity, expected to close Q4 2025, funding pivotal trials and longevity offerings. Redemptions could trim Launch One's $239.7 million trust cash. Yet risks loom if approvals falter.
10-Q
Q1 FY2025 results
Launch One Acquisition Corp. posted a net income of $2.3M for Q1 FY2025 ended March 31, 2025, driven by $2.4M in interest from its Trust Account, up sharply from a $18K loss in the prior-year stub period (derived). Operating expenses ticked up to $178K from administrative costs, yet the Trust swelled to $238M, yielding $10.35 per redeemable share. Cash outside the Trust dipped to $669K, with a $795K working capital surplus supporting the hunt for a business combination by July 2026. No debt burdens the balance sheet. Trust assets stay secure.
IPO
Sector
Industry
AAM
AA Mission Acquisition Corp.
10.65+0.03
BAYA
Bayview Acquisition Corp
11.63-0.01
BSAA
BEST SPAC I Acquisition Corp.
10.10+0.00
LCCC
Lakeshore Acquisition III Corp.
10.21+0.00
LOKV
Live Oak Acquisition Corp. V
10.27+0.02
LPBB
Launch Two Acquisition Corp.
10.46-0.01
PACH
Pioneer Acquisition I Corp
10.11+0.01
SIMA
SIM Acquisition Corp. I
10.57+0.01
SPKL
Spark I Acquisition Corp.
11.23+0.08
WLAC
Willow Lane Acquisition Corp.
11.86+0.45